Novartis Secures U.S. Approval for Pfizer-Rivaling Breast Cancer Drug

Mar 14, 2017

The U.S. Food and Drug Administration has approved Novartis' Kisqali, which is used to treat postmenopausal women who have a form of breast cancer that has been difficult to treat. The drug will challenge rival Pfizer's Ibrance as a first-line treatment for HR-positive, HER2-negative breast cancer.

Novartis has priced Kisqali, which it says has blockbuster potential, cheaper than Ibrance, with a 28-day supply, 600-mg dose costing $10,950, a 400-mg dose costing $8,760 and a 200-mg dose costing $4,380. The company estimates the meds' price at up to a 20 percent discount to Ibrance.


Kisqali is also under review in Europe.

Read the Reuters report

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments